Spero Therapeutics, Inc. (SPRO): Cash & Equivalents
$40.27M
As of 2025-12-31
$50.77M
As of 2026-06-30
-28.3%
3-year compound annual growth
-13.9%
5-year compound annual growth
+21.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $40.27M | -23.9% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $52.89M | -30.7% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $76.33M | -30.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $109.11M | -3.1% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $112.58M | +32.1% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $85.21M | +186.6% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $29.73M | -12.8% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $34.08M | -61.0% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $87.29M | +746.2% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $10.31M | +81.3% | 2018-04-02, Balance as of period end |
| 2015-12-31 | $5.69M | n/a | 2018-04-02, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $40.27M | -23.9% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $149.10M | -33.6% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $32.30M | -13.3% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $10.71M | -31.6% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $79.38M | +38.6% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $164.09M | +359.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $112.28M | +61.5% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $58.45M | +52.4% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $628.11M | -28.6% |
Compare SPRO, KURA, ENTA, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗